Synonyms: BMS986278 | compound 33 [PMID: 34709814]
Compound class:
Synthetic organic
Comment: BMS-986278 a lysophosphatidic acid receptor 1 (LPA1) antagonist [1]. It was advanced into clinical trials to determine its efficacy as a treatment for fibrotic lung conditions.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
BMS-986278 has progressed to Phase 2 clinical evaluation in participants with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04308681 | A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis | Phase 2 Interventional | Bristol-Myers Squibb | ||
NCT03981094 | A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants | Phase 1 Interventional | Bristol-Myers Squibb |